| 11.85 Data as of Jun 18 |  +0.71 / +6.37%Today’s Change | 6.25 Today|||52-Week Range 12.00 | +34.81% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $237.2M |
Company Description
Verastem, Inc. is a biopharmaceutical company, which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The company is translating discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. Its product candidates are VS-507, VS-4718 and VS-5095 these compounds may be especially beneficial as therapeutics in aggressive cancers with a high percentage of CSCs. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal and is headquartered in Cambridge, MA.
Employees
Shareholders
| Individual stakeholders | 57.46% |
| Other institutional | 16.39% |
| Mutual fund holders | 15.46% |
Top Executives
| Christoph H. Westphal, MD, PhD | Chairman & Chief Executive Officer |
| Robert M. Forrester | President & Chief Operating Officer |
| John B. Green, MBA, CPA | Chief Financial Officer |
| Joanna C. Horobin, MD | Chief Medical Officer |
| Jonathan Pachter, PhD | Vice President & Head-Research |
.
